LLRAPC Minutes July 2022(674 KB) - LMSG/LLR APC minutes
Date added: 23rd Sep 2022
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| ALISKIREN | Orange | Existing patients with Hypertension | |
| AMANTADINE | Yellow | Prolonged disorder of consciousness | |
| AMISULPRIDE (UPDATED) | Yellow | Schizophrenia | |
| ANGIOTENSIN II (Giapreza® ) (NEW) | Grey | Hypotension in adults with septic or other distributive shock | |
| ANTIPSYCHOTICS-Atypical (UPDATED) | Yellow | ||
| ARIPIPRAZOLE LONG-ACTING INJECTION (Abilify Maintena®) (UPDATED) | Yellow | Maintenance treatment of schizophrenia in patients currently stabilised on oral aripiprazole | |
| ARIPIPRAZOLE oral (UPDATED) | Yellow | Schizophrenia. Treatment and recurrence of mania. Control of agitation and disturbed behaviour in schizophrenia | |
| BALSALAZIDE (UPDATED) | Yellow | Ulcerative colitis | |
| BULEVIRTIDE (Hepcludex ®) (NEW) | Grey | Chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV-RNA positive adult patients with compensated liver disease. | |
| CATRIDECACOG (Novothirteen ®) (NEW) | Grey | Long term prophylaxis of bleeding in patients with congenital factor XIII A-subunit deficiency and bleeding episodes during regular prophylaxis. | |
| CYANOCOBALAMIN (UPDATED) | Do not prescribe | Dietary supplementation of Vitamin B12 | |
| CYANOCOBALMIN (Orobalin ®1mg tablet) (NEW) | Green | Higher strength cyanocobalmin oral product |
Only to be used where there is malabsorption of Vitamin B12 in needle phobic patients, patients with mobility issues unable/ unsuitable to attend for injections or patients where injection is not tolerated preventing the use of hydroxycobalamin injections. |
| DANTROLENE Capsules (NEW) | Orange | Chronic Spasticity in Adults | |
| DAPAGLIFLOZIN (Forxiga®) | Green | CKD in adults |
In line with NICE TA775 See CKD pathway for more information
|
| DAPSONE | Red | Dermatology | |
| DELAFLOXACIN MEGLUMINE (Quofenix®) | Red | Acute bacterial skin and skin structure infections | |
| DEXAMETHASONE / LEVOFLOXACIN EYE DROPS (Ducressa®) | Grey | Prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults. | |
| DIROXIMEL FUMERATE (Vumerity®) | Red | Relapsing-remitting multiple sclerosis |
In line with NICE TA794 |
| DOXAZOSIN M/R TABLETS | Do not prescribe | Hypertension | |
| FAMOTIDINE | Green | H2 antagonist | |
| FARICIMAB (Vabysmo®) (NEW) | Red | Wet age-related macular degeneration |
In line with NICE TA800 |
| FILGOTINIB (Jyseleca®) | Red | Moderate to severe active ulcerative colitis |
In line with NICE TA792 Implementation date 1st September 2022 |
| FINERENONE (Kerendia®) | Grey | Treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. | |
| FLUPENTIXOL DECANOATE (UPDATED) | Yellow | Schizophrenia | |
| FLUPHENAZINE DECANOATE (UPDATED) | Yellow | Schizophrenia | |
| FORMOTEROL/BUDESONIDE/GLYCOPYRRONIUM INHALER (Trixeo Aerospace®) | Do not prescribe | Moderate to severe COPD |
Reviewed by the Respiratory Prescribing Group May 2022 |
| HALOPERIDOL DECANOATE (UPDATED) | Yellow | Schizophrenia | |
| HYDROXYCHLOROQUINE | Yellow | Dermatological conditions |
Eye checks to be organised by secondary care |
| INCLISIRAN (Leqvio®) | Green | Treating primary hypercholesterolaemia or mixed dyslipidaemia. SECONDARY PREVENTION ONLY as per NICE TA733 |
For prescribers who feel competent to use this medication. In line with NICE TA733. For further related guidance please see the Cardiovascular Guidelines page. This page also includes an interim inclisiran pathway.
|
| IQoro® | Grey | Neuromuscular training device | |
| LURASIDONE (UPDATED) | Yellow | schizophrenia | |
| LYUMJEV | Green | Fast acting insulin for adults with diabetes mellitus | |
| MEPACRINE | Red | Refractory giardiasis | |
| MESALAZINE ORAL (prescribe by brand) (UPDATED) | Yellow | Ulcerative colitis, Crohn's disease and paediatric colitis |
Monitoring for paediatrics done by secondary care |
| OLANZAPINE Oral (UPDATED) | Yellow | Schizophrenia. Combination therapy for mania. Preventing recurrence in bipolar disorder. Monotherapy for mania. Control of agitation and disturbed behaviour in schizophrenia or mania. Personality disorder. | |
| ORITAVANCIN (Tenkasi®) | Grey | Acute bacterial skin and skin structure infections | |
| PALIPERIDONE PALMITATE Long-Acting Injection (UPDATED) | Yellow | Maintenance in schizophrenia in patients previously responsive to risperidone. | |
| PERINDOPRIL ARGINE | Do not prescribe | Hypertension | |
| PLENVU | Red | Bowel cleansing | |
| POTASSIUM PERMANGANATE | Red | Dermatology |
External use only |
| QUETIAPINE (UPDATED) | Yellow | Schizophrenia. Mania (either alone or in combination with mood stabilisers). Depression in bipolar disorder. Adjunctive treatment in major depressive disorder. Personality disorder. |
See Antipsychotic Prescribing Guide |
| RISPERIDONE LONG-ACTING INJECTION (Risperdal Consta®) (UPDATED) | Yellow | Schizophrenia and other psychoses in patients tolerant to oral risperidone. | |
| RISPERIDONE Oral (UPDATED) | Yellow | Acute and chronic psychoses. Mania. Short term (up to 6 weeks) of persistent aggression in patients with moderate to severe AD. Short term (up to 6 weeks) treatment of persistent aggression in conduct disorder. Personality disorder. | |
| ROMOSOZUMAB (Evenity®) | Red | Severe osteoporosis |
In line with NICE TA791 Implementation date 25th August 2022 |
| SOMATROGON (Ngenla®) | Grey | Treatment of children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone. | |
| STRONTIUM RANELATE | Red | Severe postmenopausal osteoporosis to reduce the risk of vertebral & non-vertebral fractures in patients without established cardiovascular disease when other treatments are contraindicated | |
| SUCRALFATE ENEMAS | Red | Radiation proctitis | |
| SULFASALAZINE ORAL & RECTAL | Orange | Ulcerative colitis and Crohn's disease |
Shared care request is mandatory |
| TransiSoft® | Do not prescribe | Chronic constipation, use usually limited to 2 weeks |
Not to be confused with other macrogol products such as Macrogol oral powder compound e.g. Laxido or Movicol |
| TRIFAROTENE (Aklief®) (NEW) | Grey | Cutaneous treatment of Acne Vulgaris | |
| VOXELTOR | Red | Haemolytic anaemia in adults and paediatric patients 12 years of age and older with sickle cell disease |
Under the EAMS scheme |
| ZUCLOPENTHIXOL DECANOATE (Clopixol® Depot and Clopixol® Conc.) (UPDATED) | Yellow | Schizophrenia |
See Antipsychotic Prescribing Guide |
Other Updates on this Website
Recent documents from LLR APC and TAS
LLRAPC Newsletter- September 22(659 KB) - LMSG/LLR APC newsletters
Date added: 16th Sep 2022
SCA: Sulfasalzaine for IBD(688 KB) - Shared care agreement
From 1st September 2022
Date added: 1st Aug 2022
Antipsychotic prescribing guide for Primary Care(418 KB) - Guidelines
Version 1
Date added: 29th Jul 2022
Blood Glucose Test Strip and Insulin Pen Needles Preferred List(541 KB) - Guidelines
Version 3.5 Uploaded July September 2022
Date added: 6th Jun 2019
Antimicrobial Policy and Guidance for Primary Care(1 MB) - Guidelines
Updated version Uploaded September 22
Date added: 2nd May 2019
Leicestershire Traffic Light Criteria Guidelines(622 KB) - Leicestershire traffic light system
Version 3.2 Uploaded September 2022
Date added: 4th Jun 2015
Clostridium Difficile Care Pathway(350 KB) - Guidelines
Version 7 Uploaded September 22
Date added: 1st Jun 2015
LMSG Members(393 KB) - Uncategorised
Interim membership 2022
Date added: 28th May 2015
SCA: Testosterone(559 KB) - Shared care agreement
Version 2.2 Uploaded September 2022
Date added: 20th May 2015
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more